Academic Journal
View in EDS
Linked Full Text

First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis

Bibliographic Details
Title: First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis
Authors: Domenico Ciliberto, Giulio Caridà, Nicoletta Staropoli, Caterina Romeo, Grazia Maria Arillotta, Cristina Napoli, Luigia Gervasi, Francesco Luciano, Caterina Riillo, Pierfrancesco Tassone, Pierosandro Tagliaferri
Source: Heliyon, Vol 9, Iss 8, Pp e18696- (2023)
Publisher Information: Elsevier, 2023.
Publication Year: 2023
Collection: LCC:Science (General)
LCC:Social sciences (General)
Subject Terms: HCC, Advanced hepatocellular carcinoma, TKI, ICI, Sorafenib, Lenvatinib, Science (General), Q1-390, Social sciences (General), H1-99
More Details: The rapid development of novel therapeutic options for advanced hepatocellular carcinoma (aHCC) has generated some uncertainty about the rational choice of the systemic upfront treatment. So far, a variety of therapeutic strategies have been investigated, including the combination of immunecheckpoint inhibitors and anti-VEGF. To identify the treatment that should be preferred as front-line approach, we compared the efficacy and toxicity of a variety of therapeutic strategies. With this aim, we performed a systematic review and a meta-analysis of randomized clinical trials. OS, PFS, ORR and tolerability outcomes were considered, and for each outcome the treatment ranking was evaluated by the surface under the cumulative rankings (SUCRAs). Combination of Camrelizumab + Rivoceranib scored the best in OS, followed by Sintilimab + Bevacizumab, whereas Lenvatinib + Pembrolizumab showed higher probability to be the best treatment in PFS and Sintilimab + Bevacizumab performed best in ORR. Finally, Durvalumab is the most tolerated treatment.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2405-8440
Relation: http://www.sciencedirect.com/science/article/pii/S2405844023059042; https://doaj.org/toc/2405-8440
DOI: 10.1016/j.heliyon.2023.e18696
Access URL: https://doaj.org/article/fb2e6fd54a394d6ab96df15017f50d9f
Accession Number: edsdoj.fb2e6fd54a394d6ab96df15017f50d9f
Database: Directory of Open Access Journals
FullText Links:
  – Type: other
    Url: https://resolver.ebsco.com:443/public/rma-ftfapi/ejs/direct?AccessToken=43B5AC4E196537FB838F&Show=Object
Text:
  Availability: 0
CustomLinks:
  – Url: https://www.doi.org/10.1016/j.heliyon.2023.e18696?
    Name: ScienceDirect (all content)-s8985755
    Category: fullText
    Text: View record from ScienceDirect
    MouseOverText: View record from ScienceDirect
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edsdoj&genre=article&issn=24058440&ISBN=&volume=9&issue=8&date=20230801&spage=&pages=&title=Heliyon&atitle=First-line%20systemic%20treatment%20for%20hepatocellular%20carcinoma%3A%20A%20systematic%20review%20and%20network%20meta-analysis&aulast=Domenico%20Ciliberto&id=DOI:10.1016/j.heliyon.2023.e18696
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
  – Url: https://doaj.org/article/fb2e6fd54a394d6ab96df15017f50d9f
    Name: EDS - DOAJ (s8985755)
    Category: fullText
    Text: View record from DOAJ
    MouseOverText: View record from DOAJ
Header DbId: edsdoj
DbLabel: Directory of Open Access Journals
An: edsdoj.fb2e6fd54a394d6ab96df15017f50d9f
RelevancyScore: 975
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 975.242797851563
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Domenico+Ciliberto%22">Domenico Ciliberto</searchLink><br /><searchLink fieldCode="AR" term="%22Giulio+Caridà%22">Giulio Caridà</searchLink><br /><searchLink fieldCode="AR" term="%22Nicoletta+Staropoli%22">Nicoletta Staropoli</searchLink><br /><searchLink fieldCode="AR" term="%22Caterina+Romeo%22">Caterina Romeo</searchLink><br /><searchLink fieldCode="AR" term="%22Grazia+Maria+Arillotta%22">Grazia Maria Arillotta</searchLink><br /><searchLink fieldCode="AR" term="%22Cristina+Napoli%22">Cristina Napoli</searchLink><br /><searchLink fieldCode="AR" term="%22Luigia+Gervasi%22">Luigia Gervasi</searchLink><br /><searchLink fieldCode="AR" term="%22Francesco+Luciano%22">Francesco Luciano</searchLink><br /><searchLink fieldCode="AR" term="%22Caterina+Riillo%22">Caterina Riillo</searchLink><br /><searchLink fieldCode="AR" term="%22Pierfrancesco+Tassone%22">Pierfrancesco Tassone</searchLink><br /><searchLink fieldCode="AR" term="%22Pierosandro+Tagliaferri%22">Pierosandro Tagliaferri</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Heliyon, Vol 9, Iss 8, Pp e18696- (2023)
– Name: Publisher
  Label: Publisher Information
  Group: PubInfo
  Data: Elsevier, 2023.
– Name: DatePubCY
  Label: Publication Year
  Group: Date
  Data: 2023
– Name: Subset
  Label: Collection
  Group: HoldingsInfo
  Data: LCC:Science (General)<br />LCC:Social sciences (General)
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22HCC%22">HCC</searchLink><br /><searchLink fieldCode="DE" term="%22Advanced+hepatocellular+carcinoma%22">Advanced hepatocellular carcinoma</searchLink><br /><searchLink fieldCode="DE" term="%22TKI%22">TKI</searchLink><br /><searchLink fieldCode="DE" term="%22ICI%22">ICI</searchLink><br /><searchLink fieldCode="DE" term="%22Sorafenib%22">Sorafenib</searchLink><br /><searchLink fieldCode="DE" term="%22Lenvatinib%22">Lenvatinib</searchLink><br /><searchLink fieldCode="DE" term="%22Science+%28General%29%22">Science (General)</searchLink><br /><searchLink fieldCode="DE" term="%22Q1-390%22">Q1-390</searchLink><br /><searchLink fieldCode="DE" term="%22Social+sciences+%28General%29%22">Social sciences (General)</searchLink><br /><searchLink fieldCode="DE" term="%22H1-99%22">H1-99</searchLink>
– Name: Abstract
  Label: Description
  Group: Ab
  Data: The rapid development of novel therapeutic options for advanced hepatocellular carcinoma (aHCC) has generated some uncertainty about the rational choice of the systemic upfront treatment. So far, a variety of therapeutic strategies have been investigated, including the combination of immunecheckpoint inhibitors and anti-VEGF. To identify the treatment that should be preferred as front-line approach, we compared the efficacy and toxicity of a variety of therapeutic strategies. With this aim, we performed a systematic review and a meta-analysis of randomized clinical trials. OS, PFS, ORR and tolerability outcomes were considered, and for each outcome the treatment ranking was evaluated by the surface under the cumulative rankings (SUCRAs). Combination of Camrelizumab + Rivoceranib scored the best in OS, followed by Sintilimab + Bevacizumab, whereas Lenvatinib + Pembrolizumab showed higher probability to be the best treatment in PFS and Sintilimab + Bevacizumab performed best in ORR. Finally, Durvalumab is the most tolerated treatment.
– Name: TypeDocument
  Label: Document Type
  Group: TypDoc
  Data: article
– Name: Format
  Label: File Description
  Group: SrcInfo
  Data: electronic resource
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: ISSN
  Label: ISSN
  Group: ISSN
  Data: 2405-8440
– Name: NoteTitleSource
  Label: Relation
  Group: SrcInfo
  Data: http://www.sciencedirect.com/science/article/pii/S2405844023059042; https://doaj.org/toc/2405-8440
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.1016/j.heliyon.2023.e18696
– Name: URL
  Label: Access URL
  Group: URL
  Data: <link linkTarget="URL" linkTerm="https://doaj.org/article/fb2e6fd54a394d6ab96df15017f50d9f" linkWindow="_blank">https://doaj.org/article/fb2e6fd54a394d6ab96df15017f50d9f</link>
– Name: AN
  Label: Accession Number
  Group: ID
  Data: edsdoj.fb2e6fd54a394d6ab96df15017f50d9f
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.fb2e6fd54a394d6ab96df15017f50d9f
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.heliyon.2023.e18696
    Languages:
      – Text: English
    Subjects:
      – SubjectFull: HCC
        Type: general
      – SubjectFull: Advanced hepatocellular carcinoma
        Type: general
      – SubjectFull: TKI
        Type: general
      – SubjectFull: ICI
        Type: general
      – SubjectFull: Sorafenib
        Type: general
      – SubjectFull: Lenvatinib
        Type: general
      – SubjectFull: Science (General)
        Type: general
      – SubjectFull: Q1-390
        Type: general
      – SubjectFull: Social sciences (General)
        Type: general
      – SubjectFull: H1-99
        Type: general
    Titles:
      – TitleFull: First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Domenico Ciliberto
      – PersonEntity:
          Name:
            NameFull: Giulio Caridà
      – PersonEntity:
          Name:
            NameFull: Nicoletta Staropoli
      – PersonEntity:
          Name:
            NameFull: Caterina Romeo
      – PersonEntity:
          Name:
            NameFull: Grazia Maria Arillotta
      – PersonEntity:
          Name:
            NameFull: Cristina Napoli
      – PersonEntity:
          Name:
            NameFull: Luigia Gervasi
      – PersonEntity:
          Name:
            NameFull: Francesco Luciano
      – PersonEntity:
          Name:
            NameFull: Caterina Riillo
      – PersonEntity:
          Name:
            NameFull: Pierfrancesco Tassone
      – PersonEntity:
          Name:
            NameFull: Pierosandro Tagliaferri
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 24058440
          Numbering:
            – Type: volume
              Value: 9
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Heliyon
              Type: main
ResultId 1